Page last updated: 2024-11-04

alpha-ketoglutaramate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alpha-ketoglutaramate (AKG) is an important intermediate in the citric acid cycle, a key metabolic pathway in all living organisms. It is synthesized from alpha-ketoglutarate, a molecule produced during the breakdown of glucose. AKG is a substrate for several enzymes, including glutamate dehydrogenase and transaminases. AKG is also a precursor to glutamate, an important neurotransmitter. It is involved in the biosynthesis of amino acids and the regulation of cell growth and differentiation. It is studied because of its potential role in various diseases, including cancer, diabetes, and neurodegenerative disorders. Researchers are exploring its potential use as a therapeutic agent for these conditions.'

alpha-ketoglutaramate: deaminated metabolite of glutamine in csf of patients with hepatic coma; intermediate in the detoxification of ammonia in brain; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID48
CHEBI ID30882
SCHEMBL ID1062796
MeSH IDM0051909

Synonyms (15)

Synonym
5-amino-2,5-dioxopentanoic acid
CHEBI:30882
2-oxoglutaramic acid
C00940
2-ketoglutaramate
18465-19-5
alpha-ketoglutaramate
2-keto-glutaramic acid
pentanoic acid, 5-amino-2,5-dioxo-
SCHEMBL1062796
5-amino-2,5-dioxo-pentanoic acid
DTXSID60171604
4-carbamoyl-2-oxobutanoic acid
Q27104163
5-amino-2,5-dioxopentanoicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Amino acid synthesis and interconversion (transamination)2343
Glutamate and glutamine metabolism1127

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's1 (7.14)18.2507
2000's3 (21.43)29.6817
2010's7 (50.00)24.3611
2020's2 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.59 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (18.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]